Neurocentrx

Neurocentrx is a company headquartered in the United Kingdom. Its most recent tracked round is Seed. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Neurocentrx Pharma develops oral ketamine formulations and digital prescription software to provide safer, accessible treatments for major mental health conditions, focusing on treatment-resistant major depressive disorder and bipolar depression.